Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

Phase 2

Terminated

Conditions: Gastrointestinal Stromal Tumor (GIST)

Interventions: Biological: Olaratumab

First Posted Date: 2011-03-16

Last Posted Date: 2017-03-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 21

Registration Number: NCT01316263

Locations: 🇪🇸
ImClone Investigational Site, Madrid, Spain

A Study to Compare Two Forms of LY2608204 in Healthy People

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: LY2608204 Reference
Drug: LY2608204 Test

First Posted Date: 2011-03-11

Last Posted Date: 2018-10-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT01313286

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore

A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.

Phase 1

Completed

Conditions: Diabetes Mellitus, Type II

Interventions: Biological: LY2189265

First Posted Date: 2011-02-23

Last Posted Date: 2014-10-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 30

Registration Number: NCT01301092

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States

Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Biological: LY2189265
Drug: Placebo
Drug: Insulin
Drug: Glucose
Drug: Glucagon

First Posted Date: 2011-02-21

Last Posted Date: 2014-10-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 32

Registration Number: NCT01300260

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany

Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: LY3009104

First Posted Date: 2011-02-18

Last Posted Date: 2017-06-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 6

Registration Number: NCT01299285

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States

A Study in Prevention of Re-emergence of Depression Symptoms

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: LY2216684
Drug: SSRI
Drug: Placebo

First Posted Date: 2011-02-18

Last Posted Date: 2018-04-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1249

Registration Number: NCT01299272

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Diyarbakir, Turkey

C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: LY2603618
Drug: Pemetrexed
Drug: Gemcitabine

First Posted Date: 2011-02-15

Last Posted Date: 2019-01-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 3

Registration Number: NCT01296568

Locations: 🇨🇭
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bruderholz, Switzerland

A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Biological: IMC-3C5

First Posted Date: 2011-02-03

Last Posted Date: 2019-06-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 44

Registration Number: NCT01288989

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States

A Study of LY2875358 in Participants With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: LY2875358
Drug: LY2875358 + erlotinib
Drug: LY2875358 at Part A highest dose
Drug: LY2875358 at Part A highest dose + trametinib

First Posted Date: 2011-02-01

Last Posted Date: 2017-02-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 117

Registration Number: NCT01287546

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of California - San Diego, La Jolla, California, United States
🇺🇸
Mayo Clinic of Jacksonville, Jacksonville, Florida, United States

and more 7 locations

A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: LY2090314
Drug: pemetrexed
Drug: Carboplatin
Other: ranitidine

First Posted Date: 2011-02-01

Last Posted Date: 2019-02-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 41

Registration Number: NCT01287520

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy